Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Trial Profile

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Ingenol disoxate (Primary)
  • Indications Actinic keratosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 12 Jan 2017 Results assessing efficacy and tolerability published in the British Journal of Dermatology (2017).
    • 08 Mar 2016 Primary endpoint has been met. (Part 2: Reduction in AK count), as per results presented at the 74th Annual Meeting of the American Academy of Dermatology.
    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top